South Korean FDA Probes Roche for Aiding Tamiflu Stockpiling
By Shirley S. Wang
Should companies be allowed to buy large quantities of medicine like Tamiflu to have on hand in case their employees develop the H1N1 flu virus? Not according to the law in South Korea, where it’s illegal for non-medical professionals to purchase big lots of drugs. Punishment is up to five years in prison.
The law is at the center of a probe of Tamiflu maker Roche, which is being investigated by the Korean … Continue Reading
There’s lot of action these days aimed at curbing the abuse of prescription drugs. The FDA is working on a plan to make it harder for people to get access to unauthorized prescription painkillers, pain specialists have come out with guidelines to help doctors manage pain-drug-abusing patients and drug companies have been developing abuse-resistant drugs.
Pfizer’s huge R&D shop is even bigger now that the company has swallowed Wyeth. To get a sense of the changes that could be in store, the Health Blog spoke today with the company’s two top R&D execs — Martin Mackay, a Pfizer veteran who will lead small-molecule work, and Mikael Dolsten, a former Wyeth executive who will oversee vaccines and biotech drugs.
For a look back at a key breakthrough in the history of the pharmaceutical industry, we turn now to Joe Davis, a retired ad guy who lives in Vermont.
Johnson & Johnson’s third-quarter earnings, out today, provide the latest reminder of why other drugmakers want to be more like J&J.